Benitec Biopharma Inc. - 8-K Filing
Benitec Biopharma receives formal feedback from FDA following Type C meeting for BB-301 pivotal study (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $BNTC
Benitec Biopharma receives formal feedback from FDA following Type C meeting for BB-301 pivotal study (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $BNTC